Oncolytic adenovirus

Tetherex Pharmaceuticals Signs Exclusive Worldwide License with Mayo Clinic for Development and Commercialization of a Novel Single-Cycle Adenovirus Vaccine Platform

Retrieved on: 
Tuesday, July 6, 2021

OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.

Key Points: 
  • OKLAHOMA CITY, July 6,2021 /PRNewswire/ --Tetherex Pharmaceuticals, Inc., a privately held, clinical stage biopharmaceutical company developing novel selectin inhibitor products to treat inflammatory diseases, today announced that it has executed an exclusive worldwide license with Mayo Clinic for the development and commercialization of a novel single-cycle adenovirus vaccine platform.
  • The platform will be used to target multiple infectious diseases, beginning with a Phase 1 clinical study investigating a vaccine for COVID-19.
  • The single-cycle adenovirus platform was developed to enhance the expression of target antigens, amplifying immune responses to infectious disease targets.
  • Preclinical studies have demonstrated that the single-cycle adenovirus can markedly increase target antigen expression over that of currently utilized replication defective adenovirus vaccines.

TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

Retrieved on: 
Monday, June 14, 2021

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

Key Points: 
  • TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, today announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.
  • The trial will evaluate the companys adenoviral cancer immunotherapy TILT-123, a double cytokine armed oncolytic adenovirus, in combination with KEYTRUDA (pembrolizumab), MSDs anti-PD-1 therapy, in a dose escalation trial in platinum resistant or refractory ovarian cancer patients.
  • During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter TILT-123 in conjunction with pembrolizumab.
  • TILT Biotherapeutics also announces changes to the board of directors, with Jyrki Liljeroos, formerly a board advisor, appointed as Chairman.

 TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial

Retrieved on: 
Wednesday, May 5, 2021

Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.

Key Points: 
  • Patients are being treated at Docrates Cancer Center and Helsinki University Hospital (Helsinki, Finland), leading international treatment facilities specializing in diagnostics, treatment and follow-up of cancers.\nThe \xe2\x80\x98TILT-T115\xe2\x80\x99 clinical trial (1) is a phase 1, open-label, dose-escalation study of the company\xe2\x80\x99s oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2 (IL-2), known as TILT-123.
  • A total of approximately 20 patients will receive TILT-123 as a monotherapy over a three-month period.
  • It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).\nDocrates Cancer Center is a private, Finnish-owned, international hospital in Helsinki specializing in individual and comprehensive cancer care.
  • Docrates provides services for cancer patients throughout the treatment chain from diagnosis to treatments and follow-up.

TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer

Retrieved on: 
Wednesday, April 14, 2021

During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.

Key Points: 
  • During the first month of the trial, patients will receive TILT-123 monotherapy, and thereafter consecutive treatments of TILT-123 in conjunction with pembrolizumab.
  • The heart of our approach revolves around the use of oncolytic adenoviruses armed with cytokines to boost the patient\xe2\x80\x99s immune response towards the tumor, enabling it to find and destroy cancer cells.
  • TILT\xe2\x80\x99s lead asset, TILT-123, is a 5/3 chimeric serotype adenovirus armed with two human cytokines; TNF alpha and IL-2.
  • It has funding from Lifeline Ventures, angel investors, Business Finland, and the European Innovation Council (EIC).

Transgene Presents Initial Phase I Data of TG6002, Highlighting the Potential of the Intravenous Administration of Its Oncolytic Viruses

Retrieved on: 
Friday, April 9, 2021

To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.

Key Points: 
  • To-date, the only oncolytic virus that has received regulatory approval is only approved for intra-tumoral administration, restricting its use to superficial lesions.
  • The findings that will be presented at AACR demonstrate the relevance of intravenous administration of Transgenes next generation oncolytic viruses including TG6002.
  • Based on the safety profile of TG6002, several dose levels have been added to the initial Phase I clinical protocol.
  • With its proprietary platform Invir.IO, Transgene is building on its viral vector engineering expertise to design a new generation of multifunctional oncolytic viruses.

FDA Authorizes Phase 1 Trial of ImmunityBio’s Novel COVID-19 Vaccine Candidate hAd5; Dual Construct is Designed to Drive Both T Cell and Antibody Immunity

Retrieved on: 
Thursday, October 15, 2020

The company anticipates launching a Phase I trial at Irvine, Calif. based Hoag Hospital this month with adult subjects up to age 55.

Key Points: 
  • The company anticipates launching a Phase I trial at Irvine, Calif. based Hoag Hospital this month with adult subjects up to age 55.
  • The hAd5-COVID-19 vaccine candidate is a novel, engineered, second-generation human adenovirus serotype 5 vaccine.
  • Furthermore, studies have shown that patients with SARS-CoV infection have long-term T cell memory to the N protein.
  • ImmunityBios hAd5 second generation adenovirus platform has four deletions which overcome pre-existing adenoviral immunity allowing for multiple administrations.

Aprea Therapeutics Launches Disease Awareness Website for Healthcare Professionals, p53reactivation.com

Retrieved on: 
Wednesday, October 14, 2020

BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .

Key Points: 
  • BOSTON, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc.(Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics to reactivate mutant tumor suppressor protein, p53, today announced the launch of p53reactivation.com .
  • The new website contributes to Apreas disease awareness initiative to educate healthcare professionals on the importance of p53 mutations in cancer and reactivation of mutant p53 as a potential therapeutic option for the treatment of cancer.
  • Mutations in p53 are present in approximately half of all cancers and are often associated with poor treatment outcomes and resistance to traditional anti-cancer therapies, said Eyal Attar, M.D., Senior Vice President and Chief Medical Officer of Aprea Therapeutics.
  • Knowledge of the poor prognoses that accompany p53 mutations, the availability of diagnostic tests for their identification, and awareness of mutant p53 reactivation as a potential targeted therapeutic option, may collectively advance detection and treatment for cancer patients with this important and significant unmet medical need.

TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial

Retrieved on: 
Monday, September 28, 2020

TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.

Key Points: 
  • TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmarks Herlev hospital in Copenhagen.
  • Of the two patients dosed, both have now passed the trials 36-day primary safety endpoint having received three administrations of TILT-123 at the lowest dose.
  • TILT-123s clinical trial (1) is a phase 1, open-label, dose-escalation study of the companys oncolytic adenovirus coding for Tumor Necrosis Factor Alpha (TNF alpha) and Interleukin 2.
  • This should act as a springboard to more European trials, and our first US trials, in other solid tumors.

ImmVira and Shanghai Pharma Announce Clinical Collaboration and License Agreement for Commercialization of Novel Intratumoral Oncolytic Virus Immunotherapies

Retrieved on: 
Thursday, August 6, 2020

SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.

Key Points: 
  • SHENZHEN and SHANGHAI, August 6, 2020 /PRNewswire/ -- ImmVira Group Company and Shanghai Pharmaceuticals Holding Co., Ltd today announced a clinical collaboration and exclusive license agreement for ImmVira's MVR-T3011 intratumoral oncolytic virus program for the commercialization of novel immunotherapies to treat solid malignant tumors.
  • ImmVira's MVR-T3011 oncolytic virus program has innovated with a genetically engineered oncolytic herpes simplex virus-1 (oHSV-1) to enhance the known oncolytic effects of oHSV-1.
  • As part of the agreement, Shanghai Pharma will receive an exclusive license and gain access to ImmVira's MVR-T3011 virus for clinical development, manufacturing and commercialization within certain fields of use in mainland China, Hong Kong, Macau and Taiwan (the Greater China region).
  • ImmVira and Shanghai Pharma will collaborate on clinical trials in China with exclusive commercial rights for intratumoral therapies developed under the agreement assigned to Shanghai Pharma for the Greater China region.

TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic

Retrieved on: 
Tuesday, June 16, 2020

TILT will also use the funding to develop an innovative production process to scale up GMP manufacturing.

Key Points: 
  • TILT will also use the funding to develop an innovative production process to scale up GMP manufacturing.
  • TILT Biotherapeutics CEO, Akseli Hemminki, a biotech entrepreneur and cancer clinician who has personally treated almost 300 patients with ten different oncolytic viruses, said, This additional financing provides TILT with a solid foundation to progress our cancer immunotherapies into the clinic.
  • The latest fund raising of EUR 4.5m equity includes a EUR 0.5m convertible loan and a long-term Government loan from Business Finland of up to EUR 1.7m.
  • TILT Biotherapeutics is a clinical-stage biotechnology company developing cancer therapeutics based on its proprietary, best-in-class oncolytic adenoviruses armed with molecules including cytokines that can stimulate, or suppress, T cells.